An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
VERDICT
The label
Distribution
read at $86.38
Celcuity Inc. holds its Distribution at $86.38.
PHPhase · the trend structure carries the Distribution label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-31
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 16 days
Price
$86.38
Valuation
N/A trailing · 89.98 forward price to earnings
Values screen
PASS· score 95.6
Beta
0.16
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads FAIR VALUE — it trades at roughly a 1% discount to our $86.82 fair value.
Read at
$86.38
N/A P/E · 89.98 fwd
Our fair value
$86.82
1% discount
Analyst target (avg)
$165.00
+91% to current
Target low $148.00Analyst target rangeTarget high $178.00
▲ current $86.38 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$86.38
you are here
Conservative
$86.82
+1%
Analyst avg
$165.00
+91%
Our fair value
$86.82
+1%
Analyst high
$178.00
+106%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish — a quality-at-a-fair-price name rather than a deep-value one.
Profit margin
0.00%
Debt to equity
604.28
Analyst consensus
Strong Buy · 11 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 4.9% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 6.8% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 0.0% of assets, under the 49% limit.Pass
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Biotech bet on one drug hits fair value
Picture a lab team pinning everything on one molecule that might slow aggressive tumours. Celcuity has reached that point with Gedatolisib yet still burns cash and shows no profit, so the shares trade right at our calculated worth with almost no margin of safety.
The market already hands the stock a strong buy label and a much higher target price, yet the forward multiple sits above 92 times while return on equity remains deeply negative. Ethical screens clear the company, which removes one usual reason to step aside, but the business remains a pure clinical bet.
Risks sit in plain sight: zero current earnings, heavy dilution ahead and the usual late-stage trial failures that can wipe out most of the value overnight. At current levels the price simply matches the numbers rather than offering any cushion. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in CELC's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
CELC trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.1% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 44% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 588%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (11 analysts) rates it strong buy, with a mean price target of $169. Entered 2026-07-24 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-07-24Markup$88.38+0.1%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.1% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 44% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 588%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (11 analysts) rates it strong buy, with a mean price target of $169.
2026-07-18Markup$88.28+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 44% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 588%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (11 analysts) rates it strong buy, with a mean price target of $169.
2026-07-03Markup$88.28+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (96). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$88.28Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with near-perfect ethical score (96). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
